Sumitomo Pharma America
55 Cambridge Parkway Suite 102W
Cambridge, MA 02142
United States
Tel: +1(508)481-6700
Website: https://www.us.sumitomo-pharma.com/
About Sumitomo Pharma America
Focus Areas
We tackle unmet patient needs in the crucial fields of psychiatry and neurology, oncology, urology, women's health, rare diseases, and cell and gene therapies.
Technology
We unlock innovative science and solutions through cutting-edge technology. Advanced in-house technology platforms and data analytics capabilities de-risk and optimize clinical and commercial programs to accelerate insights in science, research, and discovery.
Advocating for Patients
We reimagine what’s possible We see people as more than the conditions they are managing. We are unwavering in our promise to advocate for patients and their families on the things that matter most to them. This promise is central to everything we do as we pursue unprecedented medical innovation.
Heritage
We are building on a legacy With Sumitomo Pharma's 125-year legacy as our foundation, Sumitomo Pharma America was formed through the consolidation of Sumitomo Pharma’s US affiliates. Our parent company, the Sumitomo Group, is over 400 years old, with an extensive history of supporting health and wellbeing.
CONNECT
166 articles about Sumitomo Pharma America
-
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
8/5/2022
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months.
-
The end of July is busy for the FDA, with Coherus, Sanofi, Acadia, Myovant and Pfizer having PDUFA dates filling the calendar. Here’s a look.
-
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
7/27/2022
Myovant Sciences announced financial results for the first quarter of fiscal year 2022 and provided other corporate updates.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - July 18, 2022
7/18/2022
Myovant Sciences announced that it approved equity awards for 9 new employees with a grant date of July 15, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022
7/13/2022
Myovant Sciences, announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022.
-
Brand Institute Partners on Brand Name Development for European Commission Approved Treatment for Advanced Hormone-Sensitive Prostate Cancer
6/17/2022
Brand Institute is proud to announce having worked with Myovant Sciences in developing the brand name ORGOVYX®, for an oral medication used to treat adult patients with advanced hormone-sensitive prostate cancer.
-
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
6/17/2022
Myovant Sciences and Pfizer Inc. announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination therapy in over 1,200 women with moderate to severe pain associated with endometriosis were published in The Lancet.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - June 16, 2022
6/16/2022
Myovant Sciences announced that it approved equity awards for 23 new employees with a grant date of June 15, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
6/3/2022
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that David Marek, Chief Executive Officer and Uneek Mehra, Chief Financial and Business Officer of Myovant Sciences, Inc., will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022.
-
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
6/2/2022
Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg).
-
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
5/10/2022
Myovant Sciences announced financial results for the fourth fiscal quarter and fiscal year ended March 31, 2022 and provided other corporate updates.
-
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
5/9/2022
Myovant Sciences and Accord Healthcare, Ltd. announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey, with the right of first negotiation if Myovant decides to enter into licensing arrangements in countries in the Middle East, Africa and India.
-
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
5/6/2022
Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application for MYFEMBREE® for the management of moderate to severe pain associated with endometriosis.
-
The FDA has extended the review period for Myfembree, following the supplemental New Drug Application from Pfizer and Myovant. Here's more about this news.
-
As May gets off to a slow start for the FDA calendar, a few companies have important target action dates.
-
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
4/29/2022
Myovant Sciences (NYSE: MYOV) today announced that the European Commission (EC) has approved the marketing authorisation application for ORGOVYX® (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
-
Myovant said that the FDA provided notice it had found deficiencies that will preclude any potential discussion of labeling or post-marketing requirements at this time.
-
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
4/12/2022
Myovant Sciences and Pfizer announced an update on the Supplemental New Drug Application for MYFEMBREE® for the management of moderate to severe pain associated with endometriosis.
-
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
2/25/2022
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of ORGOVYX® (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
-
Myovant Sciences to Present at Upcoming Investor Conferences - Feb 07, 2022
2/7/2022
Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and other members of the Myovant executive team will participate in a fireside chat at the following investor conferences: